Recombinant Human CCL22, Fc-tagged
|Product Overview :||The extracellular domain of human CCL22 (aa 25-93) is fused to the N-terminus of the Fc region of human IgG1.|
- Gene Information
- Related Products
|Description :||CCL22, also named stimulated T cell chemotactic protein (STCP1), is a CC chemokine initially isolated from clones of monocyte-derived macrophages and binds to the receptor CCR4. Human CCL22 is highly expressed in macrophage and in monocyte-derived dendritic cells and thymus. It is also found in lymph node, appendix, activated monocytes, resting and activated macrophages. May play a role in the trafficking of activated/effector T-lymphocytes to inflammatory sites and other aspects of activated T-lymphocyte physiology. CCL22 has been shown to induce chemotaxis or Ca2+ mobilization in dendritic cells, IL-2 activated NK cells and activated T lymphocytes.|
|Source :||CHO Cells|
|Form :||Lyophilized from 0.2μm-filtered solution in PBS.|
|Purity :||≥98% (SDS-PAGE)|
|Stability :||Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.|
|Storage :||Short Term Storage: +4°C; Long Term Storage: -20°C. Avoid freeze/thaw cycles.|
|Gene Name :||CCL22 chemokine (C-C motif) ligand 22 [ Homo sapiens ]|
|Official Symbol :||CCL22|
|Synonyms :||CCL22; chemokine (C-C motif) ligand 22; SCYA22, small inducible cytokine subfamily A (Cys Cys), member 22; C-C motif chemokine 22; A 152E5.1; ABCD 1; DC/B CK; MDC; MGC34554; STCP 1; MDC(1-69); CC chemokine STCP-1; macrophage-derived chemokine; small inducible cytokine A22; small-inducible cytokine A22; stimulated T cell chemotactic protein 1; stimulated T-cell chemotactic protein 1; small inducible cytokine subfamily A (Cys-Cys), member 22; ABCD-1; SCYA22; STCP-1; DC/B-CK; A-152E5.1;|
|Gene ID :||6367|
|mRNA Refseq :||NM_002990|
|Protein Refseq :||NP_002981|
|UniProt ID :||O00626|
|Chromosome Location :||16q13|
|Pathway :||Chemokine receptors bind chemokines, organism-specific biosystem; Chemokine signaling pathway, organism-specific biosystem; Chemokine signaling pathway, conserved biosystem; Class A/1 (Rhodopsin-like receptors), organism-specific biosystem; Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; GPCR ligand binding, organism-specific biosystem;|
|Function :||chemokine activity;|
|◆ Recombinant Protein|
|CCL22-2884M||Recombinant Mouse CCL22 Protein||+Inquiry|
|CCL22-081C||Active Recombinant Human CCL22 Protein (69 aa)||+Inquiry|
|CCL22-311H||Recombinant Human CCL22 Protein, His-tagged||+Inquiry|
|Ccl22-2034M||Recombinant Mouse Ccl22 Protein, Myc/DDK-tagged||+Inquiry|
|Ccl22-042C||Active Recombinant Mouse Ccl22 Protein (68 aa)||+Inquiry|
|CCL22-7728HCL||Recombinant Human CCL22 293 Cell Lysate||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
The expression of CCL22 gene is regulated by a variety of signaling pathways, including inflammatory factor-mediated signaling pathways, cytokine-mediated signaling pathways, and transcription factors.
Studies have shown that by interfering with the interaction of the CCL22 protein and its receptor CCR4, tumor growth, improve inflammatory response, and regulate autoimmune diseases can be inhibited. These findings provide potential application value for the development of corresponding therapeutic strategies.
A number of inhibitors or antagonists that interact with CCL22 proteins have been developed that block the binding of CCL22 to its receptor CCR4, thereby interfering with its biological function.
The mechanism of action of CCL22 protein in specific diseases can be studied through cell culture experiments, animal models, clinical samples, and related biochemical techniques.
There are complex interactions between CCL22 proteins and other chemokines. They may influence the migration and localization of immune cells by competing for receptors, mutual regulation of expression, etc.
Some studies have shown that in tumor immunotherapy, inhibiting the expression of CCL22 or interfering with its interaction with CCR4 can enhance the effect of immunotherapy and improve the survival rate of patients.
Customer Reviews (0)Write a review
Ask a Question for All CCL22 Products
Required fields are marked with *
My Review for All CCL22 Products
Required fields are marked with *